




DOCKET NO.: B00801.70187.US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Brenner et al.
Serial No.: 09/654,328
Confirmation No.: 5793
Filed: September 1, 2000
For: METHODS AND COMPOSITIONS FOR TREATMENT OF
INFLAMMATORY DISEASE USING CADHERIN-11 MODULATING
AGENTS
Examiner: Haddad, Maher M.
Art Unit: 1644

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP RCE Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 14th day of July, 2003.


Edward R. Gates

MAIL STOP RCE
Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT

Sir:

This amendment is filed in response to the Office Action mailed from the Patent Office on January 14, 2003 (Paper No. 14). Applicants respectfully request a three month extension of time and submit the appropriate fee concurrently herewith. Also enclosed is a Request for Continued Examination and the appropriate fee. Applicants are a small entity and hereby assert small entity status.

Telephone Interview with the Examiner

Applicants wish to thank Examiners Haddad and Chan for the opportunity to conduct a telephone interview on April 14, 2003. During that interview, the outstanding enablement rejection was discussed and Applicants agreed to submit a declaration to show that the cadherin-11-Fc fusion protein mimics an anti-cadherin antibody and that in vivo administration of cadherin-11-Fc fusion protein does not induce an active immune response.